Haemonetics (HAE) – Investment Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Haemonetics (NYSE: HAE):

• 5/28/2026 – Haemonetics had its price target raised by Citigroup Inc. from $64.00 to $70.00. They now have a “neutral” rating on the stock.
• 5/23/2026 – Haemonetics was upgraded by Wall Street Zen from “hold” to “buy”.
• 5/22/2026 – Haemonetics was upgraded by Bank of America Corporation from “neutral” to “buy”. They now have a $80.00 price target on the stock, up from $72.00.
• 5/21/2026 – Haemonetics was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.
• 5/12/2026 – Haemonetics had its “outperform” rating reaffirmed by Citigroup Inc..
• 5/12/2026 – Haemonetics had its price target lowered by Barrington Research from $94.00 to $89.00. They now have an “outperform” rating on the stock.
• 5/9/2026 – Haemonetics was downgraded by Wall Street Zen from “buy” to “hold”.
• 5/8/2026 – Haemonetics was given a new $67.00 price target by Robert W. Baird.
• 5/8/2026 – Haemonetics had its price target lowered by JPMorgan Chase & Co. from $74.00 to $62.00. They now have a “neutral” rating on the stock.
• 4/13/2026 – Haemonetics had its price target lowered by Mizuho from $80.00 to $70.00. They now have an “outperform” rating on the stock.

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.